Immuno-Oncology

Today, Immuno-Oncology focuses on ways to promote patient immune system ability to fight tumoral invasion through combinations of different treatments, including monoclonal antibodies, vaccines, immune checkpoints, CAR-T cells or small molecules.

All these rely on the 3 major components of the immune system: T cells, B cells and sentinel cells.

Whether you need to understand a treatment’s mechanism of action through pathway dissection or to set up a functional readout like cytokine release, we have specific assays ready for you.

Download cytokine release from fresh blood samples application notes
Download Insider tips for PBMC isolation Technical Note
HTRF, A Powerful Assay Platform for Immune Checkpoint Studies, Download Poster

T cell receptor

T cell activation or blockade is probably the main focus of immuno-oncology, whether in CAR-T cells (chimeric antigen receptor), checkpoint blockade inhibition, or T cell infiltration.

Understanding TCR (T cell receptor) signaling is essential to assess a potential treatment and its effects.

 

B cell receptor

As a heterogeneous population, B cells can be involved in several aspects of immunotherapy. They can produce pro- or anti-inflammatory cytokines, and B cell infiltration in the tumor micro-environment (TME) can be linked to a better prognosis.

Understanding B cell activation through the BCR (B cell receptor) is now a focus in immuno-oncology.

 

Toll like receptor

TLR are a large family of receptors expressed by sentinel cells, and play a pivotal role in innate immunity.

Ligands for TLR have been widely studied as anti-cancer therapies but the outcome is as yet unpredictable. TLR are therefore a new avenue to explore for potential cancer treatments.

 

Immune check points

Immune checkpoints and their modulation have become a major focus in immuno-oncology.

Expressed by T cells and their matching cellular partners, these proteins can be inhibitory or stimulatory. To escape destruction by the immune system, tumor cells over-express inhibitory checkpoints like PD-L1, Gal9 or HVEM thus effectively switching off the T cells infiltrated at the tumor site.

Thus, strategies for immuno-oncology can be two-fold: inhibition of checkpoint blockade to restore T cell activity or activation of stimulatory checkpoints to stimulate T cell activity. Assessing the effect of a therapeutic antibody or a small molecule on the immune checkpoint interaction is now the main challenge of Research and Drug Discovery.